MANIFEST: Multiomic Platform for Cancer Immunotherapy.

Journal: Cancer discovery
PMID: 40313120

Abstract

Immunotherapy has revolutionized survival outcomes for many patients diagnosed with cancer. However, biomarkers that can reliably distinguish treatment responders from nonresponders, predict potential life-threatening and life-changing drug-induced toxicities, or rationalize treatment choices are still lacking. In response to this unmet clinical need, we introduce Multiomic ANalysis of Immunotherapy Features Evidencing Success and Toxicity, a tumor type-agnostic platform to provide deep profiling of patients receiving immunotherapy that will enable integrative identification of biomarkers and discovery of novel targets using artificial intelligence and machine learning.

Authors

  • Kok Haw Jonathan Lim
    Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
  • Zayd Tippu
    Cancer Dynamics Laboratory, The Francis Crick Institute, London, United Kingdom.
  • Pippa G Corrie
    Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
  • Michael Hubank
    Department of Translational Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
  • James Larkin
    Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Trevor D Lawley
    Host-Microbiota Interactions Laboratory, Wellcome Sanger Institute, Hinxton, United Kingdom.
  • Mark Stares
    Edinburgh Cancer Centre, NHS Lothian, Edinburgh, United Kingdom.
  • Grant D Stewart
    Department of Surgery, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Amy Strange
    Software Engineering and Artificial Intelligence, The Francis Crick Institute, London, United Kingdom.
  • Stefan N Symeonides
    Edinburgh Cancer Centre, NHS Lothian, Edinburgh, United Kingdom.
  • Bernadett Szabados
    Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Nicholas C Turner
    The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.
  • Tom Waddell
    Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Santiago Zelenay
    Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Manuel Salto-Tellez
    Integrated Pathology Unit, Division of Molecular Pathology, The Institute of Cancer Research London and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
  • Caroline Dive
    Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Samra Turajlic
    Cancer Dynamics Laboratory, The Francis Crick Institute, London, United Kingdom.

Keywords

External Resources

Popular Topics
Recent Journals